Katie Rowe is the Operational Implementation Manager at mdgroup specializing in technology implementation and adoption. She is an experienced healthcare product and system analyst with over 15 years dedicated to launching mobile applications, optimizing the patient journey, strengthening data capture, and institutional process augmentation through embracing new technology. She has led positive tech outcomes spanning insurance, behavioral health, community-based hospital systems, and clinical trials. Ms Rowe is thrilled to bring her passion of bridging the gap between tech and operations dedicated to supporting mdgroup technology and making remarkable patient experiences.

As Vice President of Commercialization for the Patient Suite at IQVIA, Anthony Mikulaschek is responsible for the commercialization IQVIA's eCOA, eConsent, and IRT platforms. This includes pricing and sales strategies, opportunity configuration, market needs review, IQVIA technology market placement and strategy. Mr Mikulaschek has extensive experience in validated system configuration, implementation, systems integration, business process reengineering, IT operations, and consulting. He has successfully led the development, delivery, and management of technology solutions for over 37 years including 29 years in the Pharmaceutical sector.

Natasha Massias is a seasoned dynamic learning development and eCOA/ePRO professional with ten years in the clinical trials industry. Her expertise within the field is technical product training, and she has facilitated hands-on, instructor-led trainings to over 300 sites throughout her career.

Rodrigo Crispim, PharmD, MBA is lean sigma certified with over 20 years in the pharmaceutical industry. Currently, Mr Crispim manages the Novartis clinical trials’ portfolio from Latin America and Canada. Previously, he held a variety of leadership roles in clinical operations including LaCan ClinOps region head for oncology, global monitoring excellence head and global trial management innovation head. More recently, he held the position of head for trial design technology platform.

Michelle Crouthamel, PhD, head of digital science at AbbVie, is an industry thought leader in digital health, with a broad spectrum of R&D experience. She currently leads the digital health strategy as well as develops digital biomarkers and endpoints. In her previous roles, she has led drug discovery, clinical development, project management, and digital-pharma strategy and execution. She is very passionate about transforming the pharmaceutical industry to become truly patient-centric.

Jenn Curry is Head of Patient Engagement Capability at Biogen. In this role, Ms Curry is accountable for driving the capabilities that ensure the patient perspective is incorporated in a manner that optimizes the execution of patient-focused drug development and maximizes the degree of impact on participant enrollment and the participant experience in Biogen’s clinical studies. She is heavily engaged with internal leaders and external partners to support the patient engagement strategies leveraged across Biogen’s portfolio.

Ms Curry entered the field of clinical research as a Research Assistant at Massachusetts General Hospital in 2003 and shifted her focus to industry, specifically patient recruitment, in 2006. Prior to joining Biogen in 2019, she spent 9 years at AES/Acurian Inc., advancing from Project Manager to Director of Operational and Strategic Solutions.

Sourav leads clinical design and planning vertical within Drug development practice at ZS. He works across major pharma companies shaping trial design, early planning and feasibility programs

Shoibal Datta is Head, Digital Health Sciences within the Data Sciences Institute at Takeda. His team focuses on the incorporation of digital health technologies within clinical development specializing in decentralization of clinical trials, remote sensing and measurement and the development of digital health products for post-launch use.

Prior to Takeda he was Vice President of PPD Digital where he set the strategy of working with external platform partners and device manufacturers to create compliant, globally scalable approaches to conduct decentralized trials and their integration into conventional clinical research and data management processes. Prior to that, he spent 13 years at Biogen in roles within translational informatics, data sciences and as part of an innovation hub that launched MS PATHS, a learning healthcare system that utilizes technology to capture high quality data as standard of care for over 10,000 MS patients globally supporting RWE and value-based medicine initiatives.

Angela DeLuca is the Associate Vice President, Head of Global Study Operations at Amgen. Angela is responsible for leading the Site Management and Data Management organizations ensuring excellence and consistency in clinical trial execution across the portfolio.

With 20 years in the biopharmaceutical industry, Ms DeLuca has extensive oncology experience and has lived and worked in the US and Japan. She has been recognized for her ability to lead the progress of global clinical development excellence through the creation of innovative operational strategies and the early adoption of digital health initiatives, to optimize the R&D landscape to accelerate products to the global market. Before joining Amgen, she was Vice President, Oncology and Cell Therapy Clinical Operations at Takeda.

Ms DeLuca also held leadership positions at both AbbVie and Abbott, where she led the transformation of the clinical development operations, establishing a center of excellence that became an industry benchmark in clinical development. As the Head of Strategy and Operations for Portfolio Program Management, she served as a consulting partner to the R&D Leadership team, identifying and implementing innovative improvements across the R&D organization. In her role as Head of Innovation, she oversaw the Japan Design Lab team, integrating digital technologies, health technologies, big data, and predictive analytics to enhance clinical trial design and support business decision-making.

Ms DeLuca holds an MBA in Innovation from the University of North Carolina Chapel Hill, Kenan Flagler Business School, and a Bachelor’s in Chemistry from The Ohio State University. She is also a certified PMP.

Dr Shobha Dhadda is Senior Vice President of Biostatistics and Clinical Development Operational Functions for Neurology at Eisai and is responsible for leading statistical and operational strategies in clinical research. Dr Dhadda started her career in 1995 as a senior statistician in a pharma company and she focused her career in the design, conduct and analysis of clinical trials, with more than 25 years of experience working in pharmaceutical Industry covering a variety of therapeutic areas including Alzheimer’s. She has led the design of several innovative Bayesian adaptive design trials, group sequential design trials and platform trails. Dr Dhadda joined Eisai as head of statistics and soon also became the head of clinical development operations, which includes end to end functions involved in running a clinical trial, i.e., medical writing, data management, clinical operations, project management, Biostats, statistical programming, Data Science, and outsourcing.

Esther Dyson (@edyson on twitter) is the founder of Wellville (Wellville.net), a 10-year (2105-2024) nonprofit project devoted to fostering health and equitable well-being in five small communities around the US.  Ms Dyson works for Wellville full-time as the advisor to Muskegon County, MI.  In her spare time, she is also chair of TheCommonsProject.org, a nonprofit focused on interoperable identity and data access for patients, with appropriate security and privacy infrastructure.

Ms Dyson is also an active investor in health and health care, including 23andMe (former board member),  4D Healthware,  Abridge.ai, Aivo, AvanleeCare (board member). BAMF Health (board member),  Big Health, Bioz, Boundless.ai (sold to Thrive Global), Care.Coach, CareMESH, Cecelia,  Clover Health, Devoted Health, EatMyWay, Element3 Health, Eligible, Enso Relief (sold to Hinge), Epistemic.ai, Ezra.com,  Foresite, Hawthorne Effect, HealthCelerate, HealthTap, Humanest, Humanity, Iaso.ai,  Lipidio,  LuminDx, Medesk, MedicaSafe, meQuilibrium, Mindright.io, Nanowear, NeuroGeneCES, Nobil,  Nuna, Omada Health,  PatientsKnowBest, Pocket Naloxone, Prognos.ai, ProofPilot (board member), Resilient, Samaritan.city, Solera, Startup Health, Supportiv, Syllable.ai, System.com, Tega, Tocagen, Virgo SVS and X-Vax.

Emily Epstein, LMSW, is a Clinical Behavioral Health Specialist at the Genetics and Personalized Cancer Prevention Program at Weill Cornell Medicine. There, she provides valuable support to patients and their families as they navigate hereditary cancer syndromes. She has been called an "empathy advisor" due to her commitment to helping healthcare providers and researchers approach their patients with compassion and understanding. Through her experience as a patient with Hereditary Breast and Ovarian Cancer Syndrome due to a BRCA2 mutation, Ms Epstein brings awareness and perspective to panels, advisory boards and support groups. She collaborates and coordinates research to enhance patient-centered testing, coordinated care, support, and research in hereditary cancers. Ms Epstein holds a bachelor’s degree from New York University and a master’s in social work from Fordham University’s Graduate School of Social Services.